Back to today’s briefing

Story perspectives

Revolutionary Immunotherapy Targets Cancer Cells with Precision

1/16/2025

45 7

Summary

Story summary

Researchers at the University of Pennsylvania have made a groundbreaking leap in cancer treatment with a novel immunotherapy that harnesses engineered small extracellular vesicles (sEVs) to effectively target the DR5 receptor in cancer cells. This innovative method has outshined conventional DR5-targeting antibodies in lab tests and mouse models, igniting hope for solid tumor therapies as the team gears up for human clinical trials.

1 of 1

Story summary

Researchers at the University of Pennsylvania have made a groundbreaking leap in cancer treatment with a novel immunotherapy that harnesses engineered small extracellular vesicles (sEVs) to effectively target the DR5 receptor in cancer cells. This innovative method has outshined conventional DR5-targeting antibodies in lab tests and mouse models, igniting hope for solid tumor therapies as the team gears up for human clinical trials.